Open Access

ARTICLE

Paclitaxel Combined with Ticagrelor Inhibits B16F10 and Lewis Lung Carcinoma Cell Metastasis

Xingjun Meng^1,#, Zhihui Cao^2,#, Renfeng Liu^3,#, Kai Zheng⁴, Shuai Ding⁵, Yuefan Gu⁴, Yonghua Chen⁶, Jun Lv⁷, Ping Li⁸, Li Zhou⁹, Wenbo Wang¹⁰, Shiliang Ji¹¹, Hui He^12,*, Hui Yang^9,*

1 School of Life Science, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, 210023, China
2 Department of Dental, The Suzhou Hospital Affiliated of Nanjing Medical University, Suzhou, 215001, China
3 Department of Pharmacy, Children’s Hospital of Soochow University, Suzhou, 215002, China
4 Department of Ultrasonography, The Suzhou Hospital Affiliated of Nanjing Medical University, Suzhou, 215001, China
5 The First Clinical Medical School, Nanjing University of Chinese Medicine, Nanjing, 210023, China
6 Department of Clinical Laboratory, The Suzhou Hospital Affiliated of Nanjing Medical University, Suzhou, 215001, China
7 Department of Orthopaedics, The Suzhou Hospital Affiliated of Nanjing Medical University, Suzhou, 215001, China
8 Department of Nuclear Medicine, The Suzhou Hospital Affiliated of Nanjing Medical University, Suzhou, 215001, China
9 Department of Oncology, The Suzhou Hospital Affiliated of Nanjing Medical University, Suzhou, 215001, China
10 Department of Pharmacy, The First People’s Hospital of Kunshan, Suzhou, 215399, China
11 Department of Pharmacy, Town Hospital of Nanjing Medical University, Suzhou, 215163, China
12 Department of Gynaecology and Obstetrics, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, 215001, China

* Corresponding Authors: Hui He. Email: ; Hui Yang. Email:
# The authors contributed equally to this work

Oncologie 2022, 24(2), 283-294. https://doi.org/10.32604/oncologie.2022.021259

Received 05 January 2022; Accepted 29 March 2022; Issue published 29 June 2022

Abstract

It is widely accepted that tumor metastasis is the dominant factor leading to cancer-related death. Tumor metastasis is mediated by cell invasion, blood circulation and lymphatic circulation. Paclitaxel, as a common anti-tumor drug and a mitotic inhibitor, promotes microtubule assembly and inhibits microtubule depolymerization. In addition, ticagrelor, an anti-platelet drug, is used to treat acute coronary syndrome. Increasing numbers of studies have reported that platelets can facilitate tumor metastasis. Therefore, inhibiting the effects of platelets can serve as a novel therapeutic strategy for cancer. To explore the effect of anti-tumor and anti-platelet drugs on tumor progression, we chose paclitaxel and ticagrelor. Interestingly, the results demonstrated that paclitaxel and ticagrelor could not only suppress the proliferation, migration and invasion of B16F10 and LLC cells, but they could also prevent tumor metastasis to the lungs. Furthermore, the inhibitory effect of paclitaxel and ticagrelor was more apparent when both drugs were used in combination. Collectively, the current study demonstrated that the combination of paclitaxel and ticagrelor could be considered as a potential anti-tumor therapy approach.

---

Keywords

---